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Abstract
Background: We investigated the genetics of Fc receptors, which function as activating receptors on immune cells and help
to control HIV through antibody-mediated cellular cytotoxicity. Thus, Fc receptors may be important for virus immunity but
might also promote immune hyperactivation that would enhance infection.
Methodology/Principal Findings: We measured abundance of low and high activity alleles in two Fc receptor genes,
FCGR2A and FCGR3A, for persons with HIV disease, natural virus suppressors (HIV+, without disease) and healthy controls to
show whether genotypes were associated with infection and disease. Individuals homozygous for the high activity allele of
FCGR3A (158VV) were predominantly found among HIV progressors and this group was also skewed toward higher allele
frequencies for the V158 variant. Both of the HIV positive groups (progressors and natural virus suppressors) had
significantly higher frequencies of the V158 allele compared with uninfected controls. There were no apparent associations
among FCGR2A alleles and HIV status.
Conclusions/Significance: Our results indicate that high activity alleles of FCGR3A may be risk factors for HIV infection or
progression and we need to understand how allelic variants affect the balance between virus control and immune
activation.
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Introduction
The Fc receptors are a family of cell surface glycoproteins,
which bind the constant regions (Fc) of soluble antibodies. They
are implicated in diverse mechanisms of immune regulation.
Cross-linking Fc receptors causes cell activation or inhibition
depending on the individual receptor [1]. Fc receptors also help
control the half life of circulating immunoglobulins by targeting
bound antibodies to phagocytic or transport vesicles and
participate in antibody-dependent cellular cytotoxicity (ADCC)
or antibody-dependent cellular viral inhibition (ADCVI), a
mechanism wherein FCR-dependent cell activation increases the
production of chemokines that block HIV infection [2]. Fc
receptors are also found on epithelial cells [3,4], where they might
be important for cell activation and mucosal immunity.
We are trying to understand the roles for Fc receptors in HIV
transmission and disease, and how these functions would impact
the potential for vaccines to protect against sexual transmission of
this virus. Our approach is to explore the natural variation in Fc
receptor genetics, testing for relationships between high or low
activity alleles and HIV transmission or disease.
Two of the major receptors for IgG are the Fc c receptor IIa
(FCGR2A, CD32) and Fc c receptor IIIa (FCGR3A, CD16).
Allelic variants in both receptors are common and have been
linked to multiple disease risks. A single nucleotide polymorphism
(SNP) in FCGR3A, substituting histidine for arginine at position
131, was linked to recurring bacterial infection in children [5]. A
valine for phenylalanine substitution at position 158 in FCGR3A
was linked to the risk for autoimmune arthritis [6]. Both of these
SNP affect antibody binding and signaling strength. Cancer
patients treated with monoclonal antibodies Cetuximab or
Rituximab had better responses if they carried high activity FcR
alleles [7]
,[8]. Studies on disease associations and responses to
monoclonal antibody therapy demonstrate strong links between
FCGR2A or FCGR3A genotype and clinical outcomes, and
encourage studies on the roles for FCR in HIV transmission and
disease.
We postulated that HIV transmission might be impacted by
allelic variation in FCGR3A or FCGR2A, since these are
important signaling receptors that will affect immune activation
and susceptibility to infection. To test this hypothesis, we
compared allele frequencies among groups with and without
HIV infection. We also postulated that Fc receptor variation
would affect disease progression. For this test, we compared a
group of HIV-infected individuals with normally-progressing
disease and a cohort of natural virus suppressors characterized
by prolonged control of viremia without receiving antiretroviral
therapy [9]. Our results showed surprising relationships between
FCGR2A or FCGR3A genotypes and HIV disease.
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The distribution of genotypes for FCGR3A SNP rs396991
among uninfected controls was similar to published reports for
healthy African Americans [10] (42% FF, 50% VF and 8% VV)
and Caucasian Americans [10] (50% FF, 39% VF and 11% VV)
(Table 2). We noted a significant association between rs396991
and HIV status (Table 3). The presence of a V158 allele was
significantly associated with HIV infection (p=0.04 odds ratio 2.0
range 1.07–3.73). Uninfected controls had higher frequencies of
FF homozygotes when compared with either of the HIV infected
groups. Overall, the V158 allele was associated with an increased
risk of HIV infection.
The VV genotype also seemed to be associated with HIV
progression. The majority of VV genotype individuals (95%) were
found among HIV progressors and the V158 allele frequency was
highest in this group compared to uninfected or NVS groups. The
VV genotype was rare among uninfected controls and was not
found among natural virus suppressors. VF heterozygotes were
more common among NVS or HIV progressors compared to
uninfected controls.
The number of non-african American patients in our cohorts
was small (3 in NVS and 5 in progressors). We analyzed the results
by excluding them to have all African-american cohorts. Results
again showed a higher frequency of V allele in HIV+ versus
controls (p value 0.039, odds ratio 1.969 range 1.05523.676).
It would be interesting to study if these FCGR genotypes
influence correlates of HIV disease progression such as CD4 counts
or viralloads,however, inourHAARTtreated cohorts, this analysis
was not possible due to mostly undetectable viral RNA in plasma.
The CD4 counts also reflect the impact of therapy and are not true
measures of disease in these treated groups.
There was no association between FCGR2A rs1801274
genotypes and HIV sero-status. Among HIV sero-positive
patients, variation in this locus was not associated with the NVS
phenotype.
The FCGR2A FCGR3A extended haplotype showed no
evidence of linkage disequilibrium among HIV sero-negative
patients and the distribution of haplotypes was not significantly
different among HIV-positive and HIV-negative patients. How-
ever, within the group of all HIV-positive patients, the RR:FF
double homozygous genotype was associated with HIV progres-
sion. Out of 60 HIV progressors, 11 had this combined genotype
compared to 1/40 for NVS and 3/34 for HIV negative controls.
Discussion
The results presented here showed that the V158 allele of
FCGR3A was significantly associated with the risk for acquiring
HIV infection. We did not observe an impact of FCGR2A alleles
on HIV transmission in this admittedly small study. Thus, initial
HIV transmission into virus naive, seronegative hosts, was more
likely if the recipient carried high activity V158 alleles of
FCGR3A.
A previous report showed that V158 was associated with the risk
for Kaposi’s sarcoma (KS) [11], a common indicator of HIV
disease progression in the era before combination antiretroviral
therapy. Since the advent of broadly available, combination
antiretroviral therapy, HIV can be suppressed to low levels for
prolonged intervals, the rates for KS have declined and it is now
difficult to stratify HIV+ patients according to changing CD4
counts or vRNA levels. Accordingly, we elected to compare HIV+
individuals with progressing disease (requiring antiretroviral
therapy) to our NVS group. We noted higher frequencies of
FCGR3A V158 alleles among individuals with common disease.
Our conclusions were similar to Lehrnbecher, et al., that V158 is
associated with progressing HIV disease. Others showed that the
low activity RR genotype in FCGR2A, was linked to CD4+ T cell
counts declining below 200/mm
3 [12], suggesting that the high
activity alleles might be protective. Conversely, the high activity
HH genotype was also related to the risk for Pneumocystis infection,
which is an AIDS-defining illness and an independent marker of
disease progression. Interestingly, perinatal HIV transmission may
be affected by the infant’s FcGR2A HH genotype [13]. The
impact of FCGR2A variation on HIV acquisition and progression
thus remains unclear.
Similarly, it is difficult to interpret the combined FCGR3A plus
FCGR2A haplotype and its impact on HIV disease status.
Although FCGR3A allele frequency was significantly associated
with progressing disease compared to NVS donors, the combined
haplotype of FCGR3A FF plus FCGR2A RR (both homozygous
for low activity alleles) was significantly associated with the risk for
progressing disease with an odds ratio of 8.76. This finding may
indicate a strong requirement for FCGR2A (CD32) activity that is
Table 2. Genotypic and allelic frequencies of SNP rs1801274
(FCGR2A) and rs396991 (FCGR3A) in HIV negative controls,
NVS and HIV Progressors.
Controls HIV positives
NVS Progressors
FCGR2A
HH 4(13%) 9(20%) 4(11%)
HR 21(65%) 26(57%) 20(56%)
RR 7(22%) 10(22%) 12(33%)
FCGR3A
FF 36(51%) 14(33%) 21(36%)
FV 32(46%) 29(67%) 32(54%)
VV 2(2.8%) 0(0%) 6(10%)
Abbreviations: SNP, Single Nucleotide Polymorphism; NVS, Natural Virus
Suppressors.
FCGR genotypic variants (FCGR2A H131R and FCGR3A F158V) were studied in
HIV progressors, NVS as well as HIV negative controls. Genotypic and allelic
frequencies of rs396991 and rs1801274 are shown. The genotypic frequencies
of the HIV sero-negative patients are in Hardy-Weinberg equillibrium.
doi:10.1371/journal.pone.0015562.t002
Table 1. Study populations demographic.
Controls
(n=70) HIV positive
Progressors
(n=59)
NVS
(n=43)
Ethnicity AA(93%) AA(95%) AA(100%)
Gender M(38%), F(62%) M(70%), F(30%) M(49%), F(51%)
HIV status Negative Positive Positive
HAART no On HAART No HAART (except
pregnancy prophylaxis)
Abbreviations: AA, African Americans; NVS, Natural Virus Suppressors; M, Male;
F, Female; HAART, Highly Active Antiretroviral Therapy.
The populations were mostly African Americans (AA), except for a small
percentage of progressors and controls, which was composed of Caucasians
and Asians. HIV progressors contained a higher proportion of males and this
reflects our HIV clinic populations.
doi:10.1371/journal.pone.0015562.t001
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are homozygous with low activity alleles for both, capacity is
decreased for HIV suppression that involves Fc receptors for IgG.
However, when high activity alleles of FCGR3A are present, they
also carry a risk for stronger immune activation that leads
eventually to progressing disease.
Apparently, HIV transmission is enhanced among individuals
with the V158 allele, even in the absence of virus-specific antibody.
A previous study evaluated Fc receptor allelic variation and HIV
infection among individuals who were vaccinated with HIV gp120
protein [14]. In that work, the FCGR2A H131 and FCGR3A
V158 alleles were both related to increased risk for HIV infection.
However, the amounts of IgG present in genital mucosa were
likely to be low and may not have formed immune complexes with
HIV. We do not support the view that virus-specific antibodies
enhance HIV infection in persons carrying the V158 allele. We
favor the interpretation that individuals with higher function
FCGR3A will have increased immune activation and higher
susceptibility to HIV transmission. This is similar to the conclusion
in Lehrnbecher, et al, where they proposed that higher immune
activation would promote KS [11]. Local immune activation
might occur because of host antibody responses to another
pathogen present in the mucosal epithelium or natural antibodies
that are forming immune complexes with IgG and activating
FCGR3A by cross-linking. The mechanism might involve cells
that are not targets for HIV infection. For example, Lehner’s
group had postulated a role for Fc receptors on epithelial cells in
the control of HIV transmission [3]. It was described recently that
thymic stromal lymphopoietin (TSLP) production in epithelial cells
was increased by HIV and could promote transmission to CD4+
target cells [15]. We are testing whether Fc receptor cross-linking
will increase TSLP production by epithelium.
Although we are mostly interested in studying the effects of Fc
receptor variation on immune activation and HIV disease, there
are other possible mechanisms that are not ruled out. For example,
antibody coating of HIV particles in the infected donor might
increase the probability of virus transmission to a naı ¨ve host
through interactions with FCR. Alternatively, some individuals
may have natural antibodies that cross-react with HIV particles,
similar to the commonly observed cross-reaction to HIV p24 [16].
Without additional studies on the mechanistic consequences of Fc
receptor variation, these models cannot be eliminated.
Our studies can be improved by increasing the sample size and
potentially, including other Fc receptor genes to create an
expanded haplotype. We have not ruled out the possible impact
on transmission or disease of genes that are close to the FCGR3A
or FCGR2A loci. Further, we do not yet have experimental data
from laboratory models that are relevant to the relationships of Fc
receptor variants with HIV transmission or disease. Our ongoing
studies are addressing these important issues.
Materials and Methods
Subjects
Blood samples for genomic DNA were obtained from 172
volunteers in three categories with respect to their HIV status
(Table 1). Forty three specimens came from a Natural Virus
Suppressor (NVS) cohort at the Institute of Human Virology [9].
NVS are HIV positive individuals who control HIV replication
without antiretroviral therapy; they were confirmed HIV-positive
by serology, detection of proviral DNA and for some cases, virus
recovery from in vitro cultures but vRNA remains mostly below
detection [9]. All members of this cohort are African American,
reflecting the population of HIV-infected individuals at our clinics
in Baltimore, MD. Another group of 59 patients with HIV disease
were receiving antiretroviral therapy and are classified as
progressors. These individuals report a variety of risk factors for
HIV and likely include cases of sexual and intravenous
transmission. We have classified them as progressors in order to
distinguish them from the other HIV+ group of natural virus
suppressors. The average times of infection for the NVS and
progressor groups were 8.1 and 8.7 years, respectively. Another
group included 70 HIV negative individuals, which served as
uninfected controls.
We used the largest sample set available to us for each group.
This resulted in different numbers of samples for control, HIV
progressors and elite controllers. Each volunteer was also asked to
report racial or ethnic identity among several choices; these racial
distributions were similar but not identical in each group. Both
males and females were represented in all groups, although the
females formed smaller percentage of the HIV progressor group, a
reflection of our HIV clinic population.
Informed written consent was obtained from all patients. The
Institutional Review Board of the University of Maryland
approved the study.
Genotyping methods
Genomic DNA from each individual was genotyped for SNP
rs396991 and rs1801274 (in FCGR3A and FCGR2A, respectively)
with the ABI prism snapshot reaction kit (Applied Biosystems, Foster
City, CA) using PCR amplified gene products. For FCGR3A, gene-
specific forward primer 59-AGTTCATCATAATTCTGACTCCT-
Table 3. Association of SNPs rs1801274 (FCGR2A) and rs396991 (FCGR3A) with HIV status.
SNP All HIV+
# vs Controls Progressors vs NVS
Genotype p-value OR (95% CI) Genotype p-value OR (95% CI)
rs396991 V allele 0.0398 2.0 (1.07–3.73) VV 0.038 ND*
rs396991+
rs1801274
FF+
RR
NS** FF+
RR
0.025 8.76(1.08–70.77)
Significant differences related to HIV status are shown. For FCGR3A, carriage of V allele was associated with increased risk of HIV seropositivity. Among HIV sero-positive
cases, there was a significant association between VV genotype (i.e., lack of allele F) and the progressor phenotype. For the FCGR2A:FCGR3A extended haplotype, the
RR:FF genotype was associated with disease progression.
Fisher’s exact test (2-tailed) p values and Odds ratios are listed where significant.
*None of the NVS donors carried the F allele, so odds ratio were not calculated.
#Include Progressors and NVS.
**Not significant.
doi:10.1371/journal.pone.0015562.t003
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were used. The forward primer differed from FCGR3B by a single
nucleotide at the 39 end to provide gene specificity. For FCGR2A, the
forward primer 59GGAAAATCCCAGAAATTCTCCC-39 and re-
verse primer 59-CAACAGCCTGACTACCTATTACCTGG-39
were used. The snapshot reaction was performed as per the instructions
in the kit. The products were run on ABI Prism 3130 DNA sequencer
and data were analyzed using the GeneMapper Analysis software
(Applied Biosystems).
Results for representative samples were confirmed by direct
sequencing of the PCR products using Big Dye Terminator V3.1
Cycle sequencing kit and a 3130 Genetic Analyzer (Applied
Biosystems, Foster City, CA).
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